The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide.

As inflation concerns persist amid Middle East geopolitical tensions and rising energy prices, healthcare stocks are positioned as defensive investments. Medtronic, a turnaround story with strong dividend history and accelerating growth, appeals to value investors. Eli Lilly, a GLP-1 drug leader expanding its pipeline, offers growth potential. Both companies benefit from healthcare's historical resilience to inflation.

10/06/2026, 10:15 PM • The Motley Fool

Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight

The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.

10/06/2026, 1:00 PM • GlobeNewswire

Why I Think These Are the 2 Smartest Stocks to Buy With $5,000 in October

Despite recent Fed rate hikes and rising Treasury yields, the article recommends two blue chip dividend stocks: AbbVie, a Dividend King with 53 consecutive years of dividend increases and strong growth prospects from new drugs, and Medtronic, which is on track to become a Dividend King with 49 consecutive years of dividend hikes and improving operational performance after recent restructuring.

10/05/2026, 3:15 PM • The Motley Fool

2 High-Yield Stocks to Buy in October Without Any Hesitation

The author recommends two high-yield dividend stocks for October: Medtronic (MDT), which has completed a business overhaul and is approaching Dividend King status with a 3.3% yield, and McCormick (MKC), a consumer staples company with 39 years of dividend increases and a 4.2% yield that is acquiring Unilever's food business to roughly double its sales.

10/04/2026, 11:15 AM • The Motley Fool

Wall Street Is Bracing for the Fed's Next Move on Rates. These 3 Stocks Win Either Way.

As Wall Street anticipates potential Fed rate hikes, healthcare stocks are positioned to weather economic uncertainty better than other sectors. Three healthcare companies—Eli Lilly, Medtronic, and Johnson & Johnson—are highlighted as resilient investments due to their strong fundamentals, diversified portfolios, and proven ability to generate growth regardless of interest rate environment.

10/03/2026, 7:15 PM • The Motley Fool

Cardiorespiratory Assessment Units Market Poised for Growth Through 2035 as Advanced Technologies and Expanding Clinical Applications Create New Opportunities

The global Cardiorespiratory Assessment Units Market is projected to grow from USD 1.48 billion in 2025 to USD 2.98 billion by 2035, expanding at a CAGR of 7.23%. Growth is driven by rising prevalence of COPD and heart failure, innovation in portable AI-enabled systems, and expanding remote care applications. However, high equipment costs and staffing requirements remain challenges. North America leads with 35.12% market share.

09/25/2026, 4:58 AM • GlobeNewswire

Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig

ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.

09/24/2026, 5:54 AM • GlobeNewswire

2 Beaten-Down Stocks to Buy Before They Bounce Back

Shopify and Intuitive Surgical, despite significant year-to-date declines of 19% and 29% respectively, present attractive buying opportunities. Shopify's strong Q2 results and AI-powered initiatives position it well in e-commerce, while Intuitive Surgical's market leadership in robotic-assisted surgery and high switching costs provide competitive advantages despite increased competition from Medtronic.

09/22/2026, 6:33 PM • The Motley Fool

R3 Vascular Appoints Lisa Wipperman Heine to its Board of Directors

R3 Vascular Inc., a medical device company developing bioresorbable scaffolds for peripheral arterial disease treatment, announced the appointment of Lisa Wipperman Heine to its Board of Directors. Heine brings over 30 years of medical technology industry experience, including previous CEO roles and board positions at multiple medical device companies. The appointment comes as R3 Vascular accelerates clinical trials and prepares for commercialization of its MAGNITUDE® technology platform.

09/21/2026, 10:00 AM • GlobeNewswire

3 Dividend Stocks to Buy and Hold for 10 Years

The article recommends three healthcare dividend stocks for long-term investors: Pfizer, Abbott Laboratories, and Medtronic. Despite recent challenges, all three companies offer strong dividend programs with growth potential. Pfizer has a promising pipeline including weight loss and cancer drugs. Abbott benefits from a diversified medical device business and recent acquisitions. Medtronic is positioned for growth through its cardiac ablation solutions and robotic surgery systems.

09/18/2026, 6:13 PM • The Motley Fool

Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?

Medtronic's stock is down 3% this year despite strong fundamentals, presenting a buying opportunity for growth-oriented investors. The company's Hugo robotic-assisted surgery system is gaining traction and eroding competitor Intuitive Surgical's market dominance. With Q1 FY2027 revenue up 13.7% YoY, raised full-year guidance, a near-Dividend King status (49 consecutive years of dividend increases), and attractive valuation metrics, analysts view the stock as undervalued compared to peers.

09/17/2026, 3:23 PM • The Motley Fool

Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive Landscape

The global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.

09/17/2026, 6:51 AM • GlobeNewswire

Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.

09/05/2026, 3:15 PM • The Motley Fool

Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.

09/04/2026, 10:54 AM • GlobeNewswire

4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Medtronic, a major medical device maker, is experiencing a recovery after a 30% decline over five years. The company achieved its strongest revenue growth in a decade (8.4% in fiscal 2026), driven by cardiovascular business expansion. With improving free cash flow, a 3.1% dividend yield, and plans to become a Dividend King, Medtronic trades at a valuation discount (18x forward earnings) compared to peers and the S&P 500.

09/03/2026, 12:05 PM • The Motley Fool